Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony D Ho

Showing results (11-20 of 377) with videos related to

Pageof 38
Sort By:
Experimental Hematology|March 6, 2025
Special issue: Bone Marrow AgingAnthony D Ho, Atsushi Iwama
Experimental Hematology|November 29, 2024
Novel techniques to quantitatively assess age-dependent alterations in biophysical properties of HSPCs and bone marrow nicheAnthony D Ho, Motomu Tanaka
Experimental Hematology|October 27, 2004
Summary of the 12th international symposium on recent advances in stem cell transplantationEdward D Ball, Anthony D Ho
Future Oncology (London, England)|April 15, 2008
Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinomaJolanta B Perz, Anthony D Ho
International Journal of Cancer|July 29, 2011
Leukemia stem cellsEike C Buss, Anthony D Ho
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|May 7, 2011
The Stromal Activity of Mesenchymal Stromal CellsWolfgang Wagner, Rainer Saffrich, Anthony D Ho
EMBO Reports|July 5, 2005
Stem cells and ageing. The potential of stem cells to overcome age-related deteriorations of the body in regenerative medicineAnthony D Ho, Wolfgang Wagner, Ulrich Mahlknecht
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 7, 2008
Complementary and alternative medicine in patients with chronic lymphocytic leukemiaManfred Hensel, Martin Zoz, Anthony D Ho
Onkologie|April 15, 2010
The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomideStefan Schmitt, Anthony D Ho, Hartmut Goldschmidt
Oncology|May 12, 2005
Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma?Bernd Kasper, Anthony D Ho, Gerlinde Egerer
Pageof 38

Showing results (11-20 of 377) with videos related to

Sort By:
Pageof 38
Experimental Hematology|March 6, 2025
Special issue: Bone Marrow AgingAnthony D Ho, Atsushi Iwama
Experimental Hematology|November 29, 2024
Novel techniques to quantitatively assess age-dependent alterations in biophysical properties of HSPCs and bone marrow nicheAnthony D Ho, Motomu Tanaka
Experimental Hematology|October 27, 2004
Summary of the 12th international symposium on recent advances in stem cell transplantationEdward D Ball, Anthony D Ho
Future Oncology (London, England)|April 15, 2008
Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinomaJolanta B Perz, Anthony D Ho
International Journal of Cancer|July 29, 2011
Leukemia stem cellsEike C Buss, Anthony D Ho
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|May 7, 2011
The Stromal Activity of Mesenchymal Stromal CellsWolfgang Wagner, Rainer Saffrich, Anthony D Ho
EMBO Reports|July 5, 2005
Stem cells and ageing. The potential of stem cells to overcome age-related deteriorations of the body in regenerative medicineAnthony D Ho, Wolfgang Wagner, Ulrich Mahlknecht
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 7, 2008
Complementary and alternative medicine in patients with chronic lymphocytic leukemiaManfred Hensel, Martin Zoz, Anthony D Ho
Onkologie|April 15, 2010
The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomideStefan Schmitt, Anthony D Ho, Hartmut Goldschmidt
Oncology|May 12, 2005
Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma?Bernd Kasper, Anthony D Ho, Gerlinde Egerer
Pageof 38